ATE252890T1 - Zusammensetzung zur verminderung von nebenwirkungen eines arzneimittels - Google Patents

Zusammensetzung zur verminderung von nebenwirkungen eines arzneimittels

Info

Publication number
ATE252890T1
ATE252890T1 AT93907459T AT93907459T ATE252890T1 AT E252890 T1 ATE252890 T1 AT E252890T1 AT 93907459 T AT93907459 T AT 93907459T AT 93907459 T AT93907459 T AT 93907459T AT E252890 T1 ATE252890 T1 AT E252890T1
Authority
AT
Austria
Prior art keywords
drug
composition
reducing side
side effects
medicinal product
Prior art date
Application number
AT93907459T
Other languages
English (en)
Inventor
Kenneth Naoyuki Matsumura
Original Assignee
Kenneth Naoyuki Matsumura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth Naoyuki Matsumura filed Critical Kenneth Naoyuki Matsumura
Application granted granted Critical
Publication of ATE252890T1 publication Critical patent/ATE252890T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT93907459T 1992-03-23 1993-03-18 Zusammensetzung zur verminderung von nebenwirkungen eines arzneimittels ATE252890T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85558692A 1992-03-23 1992-03-23
PCT/US1993/002272 WO1993018750A1 (en) 1992-03-23 1993-03-18 Method for reducing side-effects of a drug

Publications (1)

Publication Number Publication Date
ATE252890T1 true ATE252890T1 (de) 2003-11-15

Family

ID=25321624

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93907459T ATE252890T1 (de) 1992-03-23 1993-03-18 Zusammensetzung zur verminderung von nebenwirkungen eines arzneimittels

Country Status (11)

Country Link
EP (1) EP0594803B1 (de)
JP (1) JP3708958B2 (de)
KR (1) KR100400107B1 (de)
CN (1) CN1122534C (de)
AT (1) ATE252890T1 (de)
AU (1) AU672395B2 (de)
CA (1) CA2109572C (de)
DE (1) DE69333266T2 (de)
DK (1) DK0594803T3 (de)
ES (1) ES2210238T3 (de)
WO (1) WO1993018750A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2196978B1 (es) * 2001-10-26 2005-03-16 Universitat Autonoma De Barcelona Composicion farmaceutica.
JP2012146460A (ja) * 2011-01-11 2012-08-02 Sony Corp 燃料電池、燃料電池の製造方法、電子機器、酵素固定化電極、バイオセンサー、エネルギー変換素子、細胞、細胞小器官および細菌
TW201406604A (zh) 2012-08-08 2014-02-16 Kinpo Elect Inc 電動輔助裝置及電動交通工具的驅動方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4659655A (en) * 1981-11-25 1987-04-21 Bio-Response, Inc. Method for isolating product-producing cells
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4957735A (en) * 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
IT1199180B (it) * 1984-08-09 1988-12-30 Serono Ist Farm Riduzione degli effetti tossici cau sati da farmaci antrachinonici
US5030719A (en) * 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
WO1990010460A1 (en) * 1989-03-13 1990-09-20 Kenneth Naoyuki Matsumura Method for reducing side effects of a drug
WO1991017761A1 (en) * 1990-05-11 1991-11-28 The University Of Connecticut Targeted protection from cytotoxins

Also Published As

Publication number Publication date
WO1993018750A1 (en) 1993-09-30
CN1078400A (zh) 1993-11-17
EP0594803A1 (de) 1994-05-04
JP3708958B2 (ja) 2005-10-19
DE69333266D1 (de) 2003-12-04
AU672395B2 (en) 1996-10-03
CA2109572C (en) 2004-11-09
EP0594803B1 (de) 2003-10-29
DK0594803T3 (da) 2004-03-08
EP0594803A4 (de) 1995-02-22
JPH06508373A (ja) 1994-09-22
CN1122534C (zh) 2003-10-01
ES2210238T3 (es) 2004-07-01
KR100400107B1 (ko) 2003-12-24
AU3805793A (en) 1993-10-21
CA2109572A1 (en) 1993-09-30
DE69333266T2 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
FI892016A0 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten, mahdollisesti -substituoitujen 4-(-kinolin-2-yyli-metoksi)-fenyylietikkahappojen ja -esterien valmistamiseksi
EP0337256A3 (de) Verfahren zur Herstellung pharmazeutischer Mischungen
EP1316562A3 (de) Kovalente Polyethylenglykol (PEG)-Protein enthaltende Zusammensetzung
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
DE69629209D1 (de) Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
ES2028796T3 (es) Procedimiento para producir preparados farmaceuticos que contienen interferon alfa.
AU5112479A (en) Medicated animal feed based on liver meal
ATE74001T1 (de) Transdermales therapeutisches system.
DE3681031D1 (de) Pharmazeutisches praeparat zur verzoegerten freigabe von ibuprofen.
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
SE7902742L (sv) Disubstituerade 3-cefem-4-karboxylsyraderivat samt forfarande for framstellning derav
DE3381854D1 (de) Perfluorkohlenwasserstoffe als vehikel zur verabreichung von arzneimitteln.
DK0414078T3 (da) Disubstituerede (quinolin-2-yl-methoxy)phenyleddikesyrederivater
DE69027598D1 (de) Zusammensetzung zur herabsetzung der nebenwirkungen eines arzneimittels
DE69333266D1 (de) Zusammensetzung zur verminderung von nebenwirkungen eines arzneimittels
YU108691A (sh) Nove 3,3'-ditiobis (propionske kiseline) i njihovi estri
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
KR910007531A (ko) 15-케토-프로스타글란딘 화합물을 이용한 간 담즙성 질병의 치료
AU536582B2 (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
DE3862017D1 (de) Pharmazeutische zubereitung zur behandlung von tinea pedis.
FI884240A (fi) Menetelmä paikalliseen käyttöön tarkoitetun farmaseuttisen valmisteen valmistamiseksi
ES2082523T3 (es) Un medicamento de accion retardada que contiene ibuprofen y su empleo.
ATE2429T1 (de) 6-imidazol-1-yl-3-hydrazino-pyridazine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
RU93058659A (ru) Способ снижения побочных эффектов лекарства
BR9813037A (pt) Composto, processo para sua preparação, uso do mesmo, preparação farmacêutica, e, combinação desta com pelo menos uma outra substância ativa

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0594803

Country of ref document: EP

REN Ceased due to non-payment of the annual fee